Howard Hughes Medical Institute

Harbor ETF Trust and Harbor Funds Expands Boards of Trustees with Landis Zimmerman Appointment

Retrieved on: 
Thursday, August 25, 2022

In a continued effort to add creative innovation and durable value to their investment solutions and talent, the Boards of Trustees of Harbor ETF Trust and Harbor Funds have appointed Landis Zimmerman to serve on the Boards as an independent Trustee.

Key Points: 
  • In a continued effort to add creative innovation and durable value to their investment solutions and talent, the Boards of Trustees of Harbor ETF Trust and Harbor Funds have appointed Landis Zimmerman to serve on the Boards as an independent Trustee.
  • Zimmerman brings to Harbor ETF Trust and Harbor Funds decades of experience investing on behalf of prominent institutions.
  • Talent continues to be one of our critical priorities at Harbor, stated Harbor ETF Trust and Harbor Funds Chairman Charles F. McCain.
  • On behalf of our Boards of Trustees and growing number of associates, we are pleased to have Landis join our Boards.

Monod Bio Closes $25M Seed Financing to Advance Biosensor Technology Platform

Retrieved on: 
Monday, August 15, 2022

Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.

Key Points: 
  • Monod Bio , a life sciences company developing custom diagnostic biosensors that emit light to detect specific biomolecules of interest, today announced it has raised a $25M seed financing round.
  • Monod was founded in November 2021 from technology developed at David Bakers lab at the University of Washington Institute for Protein Design.
  • Our partnership with Monod Bio reflects our commitment to back extraordinary teams unlocking breakthrough innovation at the intersection of technology and life sciences.
  • Monod Bio's innovative biosensor platform technology uses computational protein engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive, and cost-effective analytical assays.

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Retrieved on: 
Thursday, July 28, 2022

Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.

Key Points: 
  • Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing.
  • Many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded and lost from the cell.
  • In cancer, protective tumor suppressors are aberrantly destroyed, allowing cancer cells to circumvent cell death, thus promoting unobstructed cell proliferation.
  • Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).

Nkarta Announces Key Senior Leadership Team Appointments

Retrieved on: 
Monday, July 25, 2022

Ralph and Yvonne have each distinguished themselves through their exceptional accomplishments, leadership of collaborative teams and valuable cross-functional contributions to Nkarta, said Paul J. Hastings, President and CEO of Nkarta.

Key Points: 
  • Ralph and Yvonne have each distinguished themselves through their exceptional accomplishments, leadership of collaborative teams and valuable cross-functional contributions to Nkarta, said Paul J. Hastings, President and CEO of Nkarta.
  • Dr. Brandenberger joined Nkarta in April 2018 and most recently served as Senior Vice President, Technical Operations.
  • Ms. Li joined Nkarta in November 2019 as Senior Vice President, Finance to lead the companys financial management, treasury, tax, accounting, and SEC reporting operations.
  • Prior to joining Nkarta, she held senior leadership roles in finance, accounting and operations at Amunix and OncoMed.

What Makes Omicron More Infectious Than Other COVID-19 Variants

Retrieved on: 
Wednesday, July 20, 2022

SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- As the Omicron variant of SARS-CoV-2 spread rapidly around the globe earlier this year, researchers at Gladstone Institutes, UC Berkeley, and the Innovative Genomics Institute used virus-like particles to identify which parts of the virus are responsible for its increased infectivity and spread.

Key Points: 
  • Compared to other variants, it has also caused more breakthrough infectionsin people previously infected with or fully vaccinated against COVID-19.
  • Scientists can also engineer new virus-like particles much faster than they can grow new variants of the live virus to study.
  • Omicron mutations in the spike protein, they discovered, made virus-like particles twice as infectious as those with the ancestral spike protein.
  • "But it also means that it could be possible for Omicron to evolve to be even more infectious if those brakes are lifted."

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair

Retrieved on: 
Tuesday, July 19, 2022

RBS is the lead member of a class of small molecules called halogenated xanthenes that is entirely owned by Provectus.

Key Points: 
  • RBS is the lead member of a class of small molecules called halogenated xanthenes that is entirely owned by Provectus.
  • Dr. Tseng is an expert in tissue regeneration and a leader in the regenerative biology and bioelectrical signaling fields.
  • Dr. Tseng has identified key factors that control limb and eye regeneration, and has also established a new model for studying embryonic eye stem cells.
  • Recent medical journal publications of hers include From Cell Death to Regeneration: Rebuilding After Injury (Front Cell Dev Biol 18;9:655048.

BlackRock and QLS Advisors Partner Through BlackRock Systematic to Invest in Biomedical Innovation

Retrieved on: 
Monday, July 18, 2022

BlackRock and QLS Advisors LLC, a life sciences technology and advisory firm, have announced a partnership through BlackRock Systematic to develop data-driven investment solutions to help accelerate biomedical innovation.

Key Points: 
  • BlackRock and QLS Advisors LLC, a life sciences technology and advisory firm, have announced a partnership through BlackRock Systematic to develop data-driven investment solutions to help accelerate biomedical innovation.
  • QLS brings an industry-leading approach to investing in life sciences that complements the work that BlackRock Systematic is doing in our actively managed portfolios.
  • QLS Advisors LLC is a life sciences technology and advisory company based in Cambridge, MA, dedicated to fostering biomedical innovation.
  • BlackRock is a trademark of BlackRock, Inc. All other trademarks are the property of their respective owners.

Colossal Biosciences and the Vertebrate Genomes Project Sequence the Asian Elephant Genome, Chromosome to Chromosome

Retrieved on: 
Tuesday, July 12, 2022

Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project (VGP ) have become the first to successfully sequence the entire Asian elephant genome, introducing a new wave of innovative and disruptive animal conservation.

Key Points: 
  • Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project (VGP ) have become the first to successfully sequence the entire Asian elephant genome, introducing a new wave of innovative and disruptive animal conservation.
  • View the full release here: https://www.businesswire.com/news/home/20220712005534/en/
    Arima Hi-C Assembly of the Asian Elephant (Elephas maximus) Genome.
  • The first phase of this landmark project which was completed in June included the sequencing, assembly, and annotation of the Asian elephant (Elephas maximus) genome.
  • Following the efforts given to the T2T human genome project, the Asian elephant will be one of the first genomes to be sequenced T2T.

Global Ophthalmology Market Report 2022: Featuring Key Players Johnson & Johnson Vision, ClearSight, PanOptica & Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022

Based on Product Type, the market was studied across Drugs, Equipment, Prescription Glasses & Lens, and Software.

Key Points: 
  • Based on Product Type, the market was studied across Drugs, Equipment, Prescription Glasses & Lens, and Software.
  • The Drugs is further studied across Allergic Conjunctivitis & Inflammation Drugs, Dry Eye Drugs, Glaucoma Drugs, and Retinal Disorder Drugs.
  • Based on End User, the market was studied across Healthcare Service Providers, Hospitals, Medical Institutes, and Research Organizations.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Lupus Research Alliance Awards 2022 Lupus Insight Prize to Immunologist Dr. Akiko Iwasaki

Retrieved on: 
Thursday, June 23, 2022

SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) awarded its 2022 Lupus Insight Prize (LIP) to Akiko Iwasaki, PhD, for her discovery of the link between endogenous retroviruses and systemic lupus erythematosus (SLE). The award was presented to Dr. Iwasaki at the 22nd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2022) by Judith James, MD, PhD, LRA Scientific Advisory Board member and Lou Kerr Chair in Biomedical Research and Chair of the Arthritis and Clinical Immunology Program at the Oklahoma Medical Research Foundation. The $100,000 award recognizes and honors an outstanding investigator who has, within the past five years, published a novel and important research insight into lupus that advances our understanding of this disease and could open new avenues for lupus diagnosis and treatment.

Key Points: 
  • SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) awarded its 2022 Lupus Insight Prize (LIP) to Akiko Iwasaki, PhD, for her discovery of the link between endogenous retroviruses and systemic lupus erythematosus (SLE).
  • "I am honored to receive this prestigious award, and I sincerely thank the Lupus Research Alliance for recognizing our research.
  • The Lupus Research Alliance, the largest nongovernmental, nonprofit research organization dedicated to lupus research worldwide, aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.
  • Because the Lupus Research Alliance's Board of Directors funds all administrative and fundraising costs, 100 percent of all donations goes to support lupus research programs.